A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Public ClinicalTrials.gov record NCT07268638. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label period for an additional 24 weeks. Participants responding to treatment will be offered the opportunity to participate in the long-term safety extension study.
Study identification
- NCT ID
- NCT07268638
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- Praliciguat (Part A) Drug
- Placebo (Part A) Other
- Praliciguat (Part B) Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 3, 2025 (Actual)
- Primary completion
- Jun 2027 (Estimated)
- Completion
- Jan 2028 (Estimated)
- Last update posted
- Oct 1, 2026
2025 – 2028
United States locations
- U.S. sites
- 30
- U.S. states
- 16
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site #2 | Chula Vista | California | 91910 | Recruiting |
| Investigator Site #28 | Garden Grove | California | 92844 | Recruiting |
| Investigator Site #14 | Los Angeles | California | 90022 | Recruiting |
| Investigator Site #12 | San Dimas | California | 91773 | Recruiting |
| Investigator Site #13 | Arvada | Colorado | 80002 | Recruiting |
| Investigator Site #17 | Boca Raton | Florida | 33431 | Recruiting |
| Investigator Site #6 | Coral Springs | Florida | 33071 | Recruiting |
| Investigator Site #25 | Hialeah | Florida | 33010 | Recruiting |
| Investigator Site #7 | Miami | Florida | 33172 | Recruiting |
| Investigator Site #8 | Orlando | Florida | 32806 | Recruiting |
| Investigator Site #29 | Augusta | Georgia | 30901 | Recruiting |
| Investigator Site # 1 | Lawrenceville | Georgia | 30046 | Recruiting |
| Investigator Site #3 | Chicago | Illinois | 60643 | Terminated |
| Investigator Site #11 | Louisville | Kentucky | 40205 | Recruiting |
| Investigator Site #24 | Worcester | Massachusetts | 01608 | Recruiting |
| Investigator Site #15 | Livonia | Michigan | 48152 | Recruiting |
| Investigator Site #10 | Pontiac | Michigan | 48341 | Recruiting |
| Investigator Site #27 | Valhalla | New York | 10595 | Recruiting |
| Investigator Site #16 | New Bern | North Carolina | 28562 | Recruiting |
| Investigator Site #20 | Cleveland | Ohio | 44106 | Recruiting |
| Investigator Site #30 | Bethlehem | Pennsylvania | 18017 | Recruiting |
| Investigator Site #19 | Bridgeville | Pennsylvania | 15017 | Recruiting |
| Investigator Site #22 | Butler | Pennsylvania | 16001 | Recruiting |
| Investigator Site #23 | Goose Creek | South Carolina | 29445 | Recruiting |
| Investigator Site #4 | Chattanooga | Tennessee | 37404 | Recruiting |
| Investigator Site #5 | Arlington | Texas | 76015 | Recruiting |
| Investigator Site #21 | Dallas | Texas | 75230 | Recruiting |
| Investigator Site #9 | Dallas | Texas | 75231 | Recruiting |
| Investigator Site #18 | Houston | Texas | 48152 | Recruiting |
| Investigator Site #26 | Roanoke | Virginia | 24014 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07268638, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2026 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07268638 live on ClinicalTrials.gov.